Objective:

To evaluate TB rates in pediatric HSCT recipients and the role of isoniazid (INH) prophylaxis in high-risk LTBI patients, focusing on specific outcomes such as incidence rates and reactivation cases.

Approach:

Key Findings:

• INH prophylaxis significantly reduced the incidence of post-HSCT TB reactivation in high-risk patients, with a reduction of X% (insert specific percentage).
• No patients in the study developed active TB during the follow-up period.
• Drug-related toxicities were minimal and manageable.

Interpretation:

The study supports the efficacy of INH prophylaxis in preventing TB reactivation in pediatric HSCT recipients at high risk for LTBI, with acceptable toxicity levels.

Limitations:

• Retrospective design may introduce bias, potentially affecting the reliability of the findings.
• Limited generalizability due to single-center study, which may not reflect broader populations.

Conclusion:

Isoniazid prophylaxis is effective in reducing TB reactivation in high-risk pediatric HSCT patients, highlighting the need for targeted TB prevention strategies in this vulnerable population, which could inform clinical guidelines.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.